NeoStem, Inc. , a leader in the emerging cellular therapy industry, today announced the expansion of its intellectual property protection surrounding its CD34 Cell Program in which it is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted.
http://ift.tt/1mMN5x4
http://ift.tt/1mMN5x4
No comments:
Post a Comment